LAS VEGAS, NV--(Marketwired - Jul 17, 2014) - Earth Science Tech, Inc. (OTCQB: ETST) ("ETST" or "the Company"), a unique biotechnology company focused on nutraceuticals, bioceuticals and dietary supplements, today announced the addition of Barry Kuttner, MD, PHD to its advisory board. Barry Joseph Kuttner, MD, PHD will help ETST bring innovative and economically accessible healing products to the US Natural Health and Wellness Market(s), including ETST Cannabinoid Class Compound CBD (Cannabidiol) hemp-based rich oil. This will also include guidance on the latest advances influencing science and technology within the nutraceutical and bioceutical markets designed to promote health and wellness benefits by utilizing CBD (Cannabidiol).
We are excited to add Barry Joseph Kuttner, MD, PHD to our advisory board and look forward to working with him as part of an emerging nutraceutical, bioceutical and dietary supplement hemp wellness company," says EST CEO, Harvey Katz PhD.
Barry Joseph Kuttner, MD, PHD is a board certified physician in Dermatology and Dermatopathology located in West Palm Beach, Florida. His 30 years of professional experience, combined with his diverse training, enables him to combine the best of conventional dermatology with the techniques and therapies of integrative and holistic dermatology. Dr. Kuttner's past research and immunology training, in addition to his functional and integrative medicine training, has contributed to his ability to optimize treatment for skin cancer, psoriasis, acne, eczema and other skin diseases.
About Barry Joseph Kuttner, MD, PHD:
Undergraduate Education: B.A., Biology at New York University, 1975
Postgraduate Education: Ph.D., Microbiology and Immunology at State University of New York Downstate Medical Center, 1982
Medical Education: M.D., State University of New York Downstate Medical College, 1982
Board Certification: American Board of Dermatology; American Board of Dermatology and American Board of Pathology special qualification in Dermatopathology.
Integrative and Functional Medicine Certifications: Diplomate, American Board of Integrative Holistic Medicine 2011; Institute for Functional Medicine Certified Practitioner 2013; Fellow in Anti-Aging, Regenerative and Functional Medicine 2013; and Diplomate, American Board of Anti-Aging and Regenerative Medicine 2013.
Barry Joseph Kuttner, MD, PHD was in private practice in the New York City area for 17 years before relocating to Palm Beach County in 2005.
Barry Joseph Kuttner, MD, PHD Publications include:
1. Kuttner, B.J. and J.J. Woodruff. Selective adherence of lymphocytes to myelinated areas of rat brain. J. Immunol. 122:1666, 1979
2. Kuttner, B.J. and J.J. Woodruff. Adherence of recirculating T and B lymphocytes to high endothelium of lymph nodes. J. Immunol. 123:1421, 1979.
3. Woodruff, J.J. and B.J. Kuttner. Adherence of lymphocytes to the endothelium of lymph nodes in vitro. In Blood Cells and Vessel Walls: functional interactions. Edited by R. Porter, M. O'connor, and J. Whalen. Elselvier-Excerpta Medica, North Holland, Amsterdam, p.243, 1980.
4. Kuttner, B.J. and J.J. Woodruff. Adherence of lymphocytes to myelinated nervous tissue in vitro. Fed. Proc. 39: ABS 3552, 1980.5. Kuttner, B.J. Selective in vitro adherence of lymphocytes to myelinated areas of rat brain: characterization of the reaction and relationship to lymphocyte binding to high endothelial cells. Doctorate Dissertation (Microbiology and Immunology). State University of New York, Downstate Medical Center, 1980.
6. Feldman, S.R. and Barry J. Kuttner. Forehead ulcer in a homosexual man. Arch. Dermatol. 122:821, 1986.
7. Kuttner, B.J. and R.J. Siegle. Treatment of chromomycosis with a CO2 laser. J. Dermatol. Surg. Oncol. 12:965, 1986.
8. Kuttner, B.J., K.J. Friedman, E.O. Olsen and C.S. Burton. Letterer-Siwe disease in an adult. Cutis 39:142, 1987.
9. Kuttner, B.J. and R.S. Kurban. Neutrophilic eccrine hidradenitis associated with acetaminophen. Cutis 41:403, 1988
10. Kuttner, B.J. A productive black facial pore. Arch. Dermatol. 125:827, 1989.
11. Kuttner, B.J., D.L. Kaplan, and M.S. Rothstein. Eruptive pruritic papules. Arch. Dermatol. 125:985, 1989
ABOUT ETST: ETST is a unique biotechnology company focused on delivering cutting edge nutraceuticals, bioceuticals and dietary supplements designed to excel in industries such as health, wellness, sports and alternative medicine to improve the quality of life for consumers worldwide. ETST is also dedicated in providing natural alternatives to prescription medications such as nutritional supplements and dietary supplements that help improve common disorders and illnesses. This may include products such as vitamins, minerals, herbs, botanicals, personal care products, homeopathics, functional foods, CBD (Cannabidiol) as a natural constituent of hemp oil and other products. These products will be in various formulations and delivery forms including but not limited to capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs.
ETST has an exclusive distribution agreement with Cromogen Biotechnologies ("Cromogen") focusing on the purchase of raw hemp-based CBD (Cannabidiol) rich oil. ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act.
Hemp oil is a well-known dietary supplement and the naturally occurring CBD in hemp is providing overwhelming evidence of significant health and wellness benefits. CBD possesses no psychoactive properties and therefore is a ready for market hemp based ingredient. According to scientific and clinical studies, CBD has the potential to help a range of conditions, including epilepsy, diabetes, rheumatoid arthritis, chronic pain, alcoholism, schizophrenia, PTSD, antibiotic-resistant infections, and various neurological disorders (Source: National Center for Biotechnology Information http://www.ncbi.nlm.nih.gov). CBD has demonstrated neurogenic and neuroprotective effects and its anti-cancer properties are currently being investigated at several academic research centers in the United States and abroad.
The Food and Drug Administration (FDA) currently considers hemp based Cannabinoids, including CBD, to be "food based" and therefore legal. These new non-psychoactive CBD-rich hemp oil products that ETST will look to market and distribute are legal and available to consumers in all fifty states and in more than forty countries. CBD (Cannabidiol), a naturally-occurring constituent of the industrial hemp plant, promotes and supports the nutritional health of aging bodies. Source: US Government patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants."
ABOUT: Cromogen Biotechnology applies a decade of research and development in plant science and phytocannabinoid studies to the manufacturing of cannabidiol-rich hemp foods and ingredients. The technology currently in place allows for the processing of 5 metric tons of hemp fiber per day, which can isolate trace amounts of phytocannabinoids as low as 300 parts per million. Common quality control concerns in the phytocannabinoid industry have been mitigated by Cromogen's R&D team through leveraging pharmaceutical processes and technology for hemp food and oil production. For more information on Cromogen visit: http://www.cromogenbiotechnology.com.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
FORWARD LOOKING DISCLAIMER: This release contains forward-looking statements that involve risks and uncertainties. Readers are referred to the Securities and Exchange Commission filings filed by the Company on EDGAR at http://www.sec.gov/edgar.shtml, specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company undertakes no obligation to review or confirm analysts' expectations or estimates or to publicly release any revisions to any forward-looking statements. The information contained in this press release should not be construed as any indication of the Company's future stock price, its revenues or results of operations.